Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)

PHASE3CompletedINTERVENTIONAL
Enrollment

426

Participants

Timeline

Start Date

July 19, 2013

Primary Completion Date

April 10, 2015

Study Completion Date

August 31, 2017

Conditions
Coronary Artery Disease
Interventions
DRUG

Gadobutrol (Gadovist, Gadavist, BAY86-4875)

Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.

Trial Locations (23)

6900

Lugano

10709

Berlin

12203

Berlin

13125

Berlin

13385

Marseille

21565

Incheon

37075

Göttingen

42055

Saint-Etienne

45122

Essen

50612

Yangsan

53115

Bonn

55455

Minneapolis

64287

Darmstadt

70376

Stuttgart

72076

Tübingen

79189

Bad Krozingen

04289

Leipzig

Unknown

Auckland

05030

Seoul

05505

Seoul

LE3 9QP

Leicester

L14 3PE

Liverpool

SW3 6NP

London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01890421 - Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD) | Biotech Hunter | Biotech Hunter